CD274 and neoplasm: The IMpassion130 trial demonstrated that among patients with untreated metastatic triple-negative breast cancer with PD-L1–positive tumours, treated with nab-paclitaxel and atezolizumab or placebo, the median overall survival was 25.0 months and 15.5 months, respectively (hazard ratio, 0.62; 95% CI, 0.45 to 0.86) [17], resulting in FDA accelerated approval.